The University of California, Davis (DC Davis) is proposing to create a Clinical and Translational Science Center (CISC) which will transform our medical research enterprise into a highly effective """"""""open"""""""" academic home for clinical and translational research by building on three key assets: 1) Our long-standing commitment as a land-grant university to serve the geographically disperse and ethnically diverse populations of inland and Northern California with a health care system enabled by one of the broadest and most extensive telecommunications programs in the world;2) The collaborative culture of DC Davis, which has one of the most extensive and interdisciplinary life science environments in the country, and 3) An established C8TC pilot facility - the UC Davis Clinical Research Investigator Services Program (CRISP) that serves as the physical home for clinical and translational research and for faculty training and career development. CRISP is a fundamentally important CTSC testing ground, where many perceived CTSA barriers have been explored and solutions tested, and through CRISP, we have completed the planning phase for the CTSC. In the organizational structure of the UC Davis CTSC, considerable attention is paid to create an organization that is: 1) responsive and familiar to investigators;2) flexible;3) well linked to university leadership, to participating academic units, and to the community;and 4) focused on the goal of reducing barriers and facilitating the translation of research gains into medical practice. Key features are: Education program focused on """"""""team science"""""""";Extensive collaborations across UC Davis colleges and centers;Introduction of catalyst functions such as Collaborative Research Facilitators and translational postdoctoral fellowships;Dissemination through tele-technology;Flexible use of resources for patientoriented research;and a Community engagement program emphasizing trust and respect. The CTSC is under the leadership of two co-Principal Investigators, Drs. Berglund MD, PhD, (P.I.) and Joseph MD, PhD (co-P.I.), supported by a team of Directors and co-Directors overseeing each of the 9 CTSC programs, and a comprehensive committee structure, designed to firmly anchor the CTSC with institutional leadership, faculty, trainees and the community. The UC Davis CTSC will be implemented through a carefully designed, collaborative plan, and the activity will be guided through continuous evaluations and corrections.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Mentored Career Development Award (KL2)
Project #
5KL2RR024144-04
Application #
7676217
Study Section
Special Emphasis Panel (ZRR1-CR-A (01))
Program Officer
Sawczuk, Andrea
Project Start
2006-09-30
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
4
Fiscal Year
2009
Total Cost
$643,140
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Mayadev, Jyoti; Lim, Jihoon; Durbin-Johnson, Blythe et al. (2018) Smoking Decreases Survival in Locally Advanced Cervical Cancer Treated With Radiation. Am J Clin Oncol 41:295-301
Bratt, Jennifer M; Chang, Kevin Y; Rabowsky, Michelle et al. (2018) Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation. J Immunol 200:3840-3856
Oskarsson, Björn; Rocke, David M; Dengel, Karsten et al. (2016) Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology 86:1159-63
Olszewski, Anna; Yanes, Amber; Stafford, Jessica et al. (2016) Development and Implementation of an Innovative Burn Nursing Handbook for Quality Improvement. J Burn Care Res 37:20-4
Godwin, Zachary; Lima, Kelly; Greenhalgh, David et al. (2016) A Retrospective Analysis of Clinical Laboratory Interferences Caused by Frequently Administered Medications in Burn Patients. J Burn Care Res 37:e10-7
Monjazeb, Arta M; Kent, Michael S; Grossenbacher, Steven K et al. (2016) Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Clin Cancer Res 22:4328-40
Oskarsson, Björn; Horton, D Kevin; Mitsumoto, Hiroshi (2015) Potential Environmental Factors in Amyotrophic Lateral Sclerosis. Neurol Clin 33:877-88
Erdembileg, Anuurad; Mirsoian, Annie; Enkhmaa, Byambaa et al. (2015) Attenuated age-impact on systemic inflammatory markers in the presence of a metabolic burden. PLoS One 10:e0121947
Henry, Stephen G; Czarnecki, Danielle; Kahn, Valerie C et al. (2015) Patient-physician communication about early stage prostate cancer: analysis of overall visit structure. Health Expect 18:1757-68
Palmieri, Tina L; Taylor, Sandra; Lawless, MaryBeth et al. (2015) Burn center volume makes a difference for burned children. Pediatr Crit Care Med 16:319-24

Showing the most recent 10 out of 41 publications